Melanie Senior has over 15 years’ experience analysing and reporting on the health care sector. She writes regularly for Informa (IN VIVO, Scrip, Datamonitor) and Nature Biotechnology, and has contributed to life sciences thought leadership at EY and produced science-based publications for the UK BioIndustry Association and other industry groups. She also helps European and international biopharmaceutical companies and fund managers to articulate their strategy and market positioning.

Melanie has covered in depth the key scientific, technological and economic forces changing the industry – from pricing reform to personalised medicine; from the impact of digital and artificial intelligence to synthetic biology; from new funding models to new business models.

Melanie began her career at the London Financial Times, moving on to become Bureau Chief, Europe, for Elsevier Business Intelligence, where she was responsible for European biopharma strategy and reimbursement content within The Pink Sheet and IN VIVO. She has also worked as a reimbursement and pricing analyst for Real Endpoints in the US.

Melanie has a first class degree in Natural Sciences from Cambridge University and a post-graduate certificate in Sports Nutrition from St. Mary’s University, Twickenham. She is currently working towards a masters in Health Technology Assessment from Sheffield University.  She speaks three European languages.